Organisation paid for research Program year 2021 Source: CMS Open Payments

Excell Research Incorporated

Neither a doctor nor a teaching hospital

Research payments

$228,249

52 payments

Through program year 2021, Excell Research Incorporated is reported as receiving $228,249 in research payments, across 52 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $5,103 7
2020 Research $3,373 6
2019 Research $219,773 39

Breakdown

Who paid Research payments · program years 2019–2021
  1. Allergan Inc. $228,249 52 payments
Studies the money was for Research payments · program years 2019–2021
  1. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $90,695 8 payments
  2. Lvm-MD-14 Preapmrphase 3Double-Blind $42,479 8 payments
  3. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $40,949 6 payments
  4. A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Rapastinel As Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder $26,150 12 payments
  5. An Open Label, Long Term Safety Study of Rapastinel As An Adjunctive Therapy in Patients With Major Depressive Disorder MDD. $9,916 1 payment
  6. A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder $3,000 1 payment
  7. A Randomized, Double-Blind, Placebo-and Active-Controlled, Multicenter Study of Rapastinel as Monotherapy in Patients with Major Depressive Disorder $3,000 1 payment
  8. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $2,630 1 payment
  9. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine $1,872 3 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine Who Have Previously Failed 2 $1,529 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record